Karus Therapeutics Strengthens Clinical Leadership Team with Appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer

Oxfordshire, UK, 17 July 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, today announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer (CMO) with immediate effect. Dr McElwaine-Johnn is a Physician with over 25 years’ experience in drug development, most recently as CMO at cancer gene […]

15-ICML International Conference on Malignant Lymphoma

18-22 June 2019 15-ICML International Conference on Malignant Lymphoma Lugano, Switzerland